Loading…
Employees: 159
Size Medistim (MEDI.OL) is a Norway Health Care company (Medical Specialties) with a market value of $601M, the 82nd largest of 115 Norway companies the cockpit tracks. Shares closed at NOK 306.00 on 6 Nov 2026.
Performance Over six months the shares gained 29.7%, against -14.2% for the median peer and +2.7% for the Norway market (cap-weighted) — 2nd highest of 20 in its peer set.
Growth Revenue grew 19.1% over the last twelve months (peer median +9.3%); the operating margin is 28.6% (peer median 7.4%).
Valuation It trades at 30.5× forward earnings against a peer median of 22.2× (4th most expensive of 11).
Price implies For today's price to make sense, revenue must grow about -2% a year for seven years (Req g). Recent delivered growth is +14%, so the hurdle is -16 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 52.3 points above its cost of capital (5.8% WACC).
Next results Next results expected around 26 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | NOK 796M | NOK 700M | NOK 563M | NOK 521M | NOK 486M |
| Revenue growth | — | +24% | +8% | +7% | — |
| Gross profit | NOK 383M | NOK 321M | NOK 245M | NOK 225M | NOK 218M |
| EBITDA | NOK 255M | NOK 219M | NOK 152M | NOK 150M | NOK 153M |
| Net income | NOK 178M | NOK 159M | NOK 104M | NOK 104M | NOK 114M |
| Free cash flow | n/a | NOK 182M | NOK 137M | NOK 96.8M | NOK 104M |
| Capital expenditure | n/a | NOK 33.0M | NOK 24.7M | NOK 29.7M | NOK 21.1M |
| Total debt | NOK 26.2M | NOK 49.3M | NOK 34.4M | NOK 17.6M | NOK 17.1M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | MEDI.OL | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +12.9% | -5.1% | 3rd highest of 20 |
| 6-month return | +29.7% | -14.2% | 2nd highest of 20 |
| Distance from 52-week high | -3.2% | -36.2% | highest of 20 |
| Revenue growth (TTM) | +19.1% | +9.3% | 2nd highest of 20 |
| Operating margin | 28.6% | 7.4% | 4th highest of 20 |
| Forward P/E | 30.5× | 22.2× | 4th most expensive of 11 |
| Growth the price implies (Req g, 7 yrs) | -1.8% | 7.8% | 2nd least demanding of 12 |
| Growth delivered (Del g) | +14.5% | +6.7% | 4th highest of 12 |
| Hurdle (Req g minus delivered) | -16.3 pp | +5.1 pp | 4th least demanding of 12 |
| ROIC minus cost of capital | +52.3 pp | -0.7 pp | 2nd highest of 18 |
| EV / EBITDA | 21.3× | 17.1× | 3rd most expensive of 6 |
| Net debt / EBITDA | -0.6× | -1.8× | 2nd most indebted of 7 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Medistim MEDI.OL | Norway | $601M | +30% | +19% | 29% | 30.5× | -1.8% | +14.5% |
| Contec Medical Systems 300869.SZ | China | $600M | -23% | -2% | -16% | n/a | 17.3% | -19.8% |
| Nanosonics NAN.AX | Australia | $599M | -13% | +3% | 7% | 90.3× | 34.4% | +6.7% |
| Wuhan Huakang Century Clean Technology 301235.SZ | China | $603M | -42% | +28% | 7% | 22.6× | n/a | n/a |
| Ningbo David Medical Device 300314.SZ | China | $607M | +22% | +19% | 11% | 12.3× | n/a | n/a |
| Hangzhou AGS MedTech 688581.SS | China | $617M | -16% | -18% | 33% | 19.8× | 1.7% | +27.8% |
| Tactile Systems Technology TCMD | United States | $583M | +1% | +14% | 9% | 20.8× | 7.8% | +12.0% |
| Zhejiang Gongdong Medical Technology 605369.SS | China | $581M | -10% | +6% | 9% | 25.2× | 11.6% | +6.5% |
| Guangdong Hybribio Biotech 300639.SZ | China | $568M | -5% | -7% | 4% | 63.8× | 2.7% | -13.2% |
| Xvivo Perfusion XVIVO.ST | Sweden | $635M | -29% | +18% | 12% | 54.2× | 35.7% | +35.2% |
| Myriad Genetics MYGN | United States | $566M | +38% | -3% | -11% | n/a | n/a | n/a |
| Sahajanand Medical Technologies SMT.NS | India | $566M | n/a | n/a | n/a | n/a | n/a | n/a |
| SunMax Biotechnology 4728.TWO | Taiwan | $643M | +1% | +12% | 50% | n/a | -0.7% | +18.8% |
| Anbio Biotechnology NNNN | United States | $560M | -85% | +10% | 67% | n/a | n/a | n/a |
| Zhejiang Orient Gene Biotech 688298.SS | China | $559M | -17% | +18% | -60% | n/a | n/a | n/a |
| Cowealth Medical China 603122.SS | China | $648M | -28% | -18% | -5% | n/a | n/a | n/a |
| MedicalSystem Biotechnology 300439.SZ | China | $556M | -4% | +14% | 2% | n/a | 7.4% | -7.8% |
| Sight Sciences SGHT | United States | $555M | -14% | +9% | -33% | n/a | n/a | n/a |
| Anteris Technologies Global AVR | United States | $555M | -14% | -10% | -4,738% | n/a | n/a | n/a |
| Nanjing Vishee Medical Technology 688580.SS | China | $550M | -40% | +7% | 24% | 21.7× | 22.3% | +4.2% |
| AK Medical 1789.HK | Hong Kong | $664M | -26% | +16% | 26% | 10.8× | -11.4% | +6.7% |